Literature DB >> 27648475

Phenanthriplatin Acts As a Covalent Poison of Topoisomerase II Cleavage Complexes.

Imogen A Riddell1, Keli Agama2, Ga Young Park1, Yves Pommier2, Stephen J Lippard1.   

Abstract

Drugs capable of trapping topoisomerase II (Top2), an essential enzyme that cleaves DNA to remove naturally occurring knots and tangles, can serve as potent anticancer agents. The monofunctional platinum agent phenanthriplatin, cis-[Pt(NH3)2(phenanthridine)Cl](NO3), is shown here to trap Top2 in addition to its known modes of inhibition of DNA and RNA polymerases. Its potency therefore combines diverse modes of action by which phenanthriplatin kills cancer cells. The observation that phenanthriplatin can act as a Top2 poison highlights opportunities to design nonclassical platinum anticancer agents with this novel mechanism of action. Such complexes have the potential to overcome current limitations with chemotherapy, such as resistance, and to provide treatment options for cancers that do not respond well to classical agents. Covalent DNA-platinum lesions implicated in Top2 poisoning are distinctive from those generated by known therapeutic topoisomerase poisons, which typically exert their action by reversible binding at the interface of Top2-DNA cleavage complexes.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27648475      PMCID: PMC5248983          DOI: 10.1021/acschembio.6b00565

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  44 in total

Review 1.  DNA topoisomerases: structure, function, and mechanism.

Authors:  J J Champoux
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

2.  Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile.

Authors:  Ga Young Park; Justin J Wilson; Ying Song; Stephen J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-06       Impact factor: 11.205

3.  Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide.

Authors:  Y Pommier; G Capranico; A Orr; K W Kohn
Journal:  Nucleic Acids Res       Date:  1991-11-11       Impact factor: 16.971

4.  Structural similarities between topoisomerases that cleave one or both DNA strands.

Authors:  J M Berger; D Fass; J C Wang; S C Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

Review 5.  The NCI60 human tumour cell line anticancer drug screen.

Authors:  Robert H Shoemaker
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

Review 6.  Topoisomerase I inhibitors: camptothecins and beyond.

Authors:  Yves Pommier
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

7.  Model for MLL translocations in therapy-related leukemia involving topoisomerase IIβ-mediated DNA strand breaks and gene proximity.

Authors:  Ian G Cowell; Zbyslaw Sondka; Kayleigh Smith; Ka Cheong Lee; Catriona M Manville; Malgorzata Sidorczuk-Lesthuruge; Holly Ashlene Rance; Kay Padget; Graham Hunter Jackson; Noritaka Adachi; Caroline A Austin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

Review 8.  Interfacial inhibitors: targeting macromolecular complexes.

Authors:  Yves Pommier; Christophe Marchand
Journal:  Nat Rev Drug Discov       Date:  2011-12-16       Impact factor: 84.694

9.  Novel HeLa topoisomerase II is the II beta isoform: complete coding sequence and homology with other type II topoisomerases.

Authors:  C A Austin; J H Sng; S Patel; L M Fisher
Journal:  Biochim Biophys Acta       Date:  1993-03-20

10.  Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino) methanesulfon-m-anisidide and adriamycin.

Authors:  L A Zwelling; S Michaels; L C Erickson; R S Ungerleider; M Nichols; K W Kohn
Journal:  Biochemistry       Date:  1981-11-10       Impact factor: 3.162

View more
  5 in total

1.  Monofunctional platinum(II) compounds and nucleolar stress: is phenanthriplatin unique?

Authors:  Christine E McDevitt; Matthew V Yglesias; Austin M Mroz; Emily C Sutton; Min Chieh Yang; Christopher H Hendon; Victoria J DeRose
Journal:  J Biol Inorg Chem       Date:  2019-09-07       Impact factor: 3.358

2.  The effect of geometric isomerism on the anticancer activity of the monofunctional platinum complex trans-[Pt(NH3)2(phenanthridine)Cl]NO3.

Authors:  Wen Zhou; Mohammad Almeqdadi; Michael E Xifaras; Imogen A Riddell; Ömer H Yilmaz; Stephen J Lippard
Journal:  Chem Commun (Camb)       Date:  2018-03-13       Impact factor: 6.222

3.  DNA Intercalation Facilitates Efficient DNA-Targeted Covalent Binding of Phenanthriplatin.

Authors:  Ali A Almaqwashi; Wen Zhou; M Nabuan Naufer; Imogen A Riddell; Ömer H Yilmaz; Stephen J Lippard; Mark C Williams
Journal:  J Am Chem Soc       Date:  2019-01-17       Impact factor: 15.419

4.  Smoothed Potential MD Simulations for Dissociation Kinetics of Etoposide To Unravel Isoform Specificity in Targeting Human Topoisomerase II.

Authors:  Jissy A Kuriappan; Neil Osheroff; Marco De Vivo
Journal:  J Chem Inf Model       Date:  2019-09-09       Impact factor: 4.956

5.  Broussochalcone A Induces Apoptosis in Human Renal Cancer Cells via ROS Level Elevation and Activation of FOXO3 Signaling Pathway.

Authors:  Han Ki Lee; Hyo Sun Cha; Myeong Jin Nam; Kyungmoon Park; Yung-Hun Yang; Jongsung Lee; See-Hyoung Park
Journal:  Oxid Med Cell Longev       Date:  2021-10-27       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.